Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Primary aldosteronism is a common cause of secondary hypertension associated with
excess cardiovascular morbidities. Primary aldosteronism is underdiagnosed because it …

Background Aldosterone synthase controls the synthesis of aldosterone and has been a
pharmacologic target for the treatment of hypertension for several decades. Selective …

This review covers the last 80 years of remarkable progress in the development of
mineralocorticoid receptor (MR) antagonists (MRAs) from synthesis of the first …

Heart Failure Society (JHFS). The working committee for this project includes members and
collaborators involved in the previous versions of the heart failure guidelines and members …

Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of
morbidity and mortality in patients with established disease. Secular trends in the …

Appropriate interpretation of changes in markers of kidney function is essential during the
treatment of acute and chronic heart failure. Historically, kidney function was primarily …

1–«МНОЦ МГУ им. МВ Ломоносова», 119192, Москва, Ломоносовский пр-кт, д. 27, корп.
10 2–ФГБОУ ВО «ПИМУ» МЗ РФ, 603950, Нижний Новгород, пл. Минина и Пожарского …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Mineralocorticoid receptor antagonists (MRAs) are key agents in guideline‐oriented drug
therapy for cardiovascular diseases such as chronic heart failure with reduced ejection …